Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy

Recipients of chimeric antigen receptor-modified T (CAR-T) cell therapies for B-cell malignancies are immunocompromised and at risk for serious infections.

Vaccine immunogenicity is unknown in this population.

We conducted a prospective observational study of the humoral immunogenicity of 2019–2020 inactivated influenza vaccines (IIV) in children and adults immediately prior to (n=7) or 13–57 months after (n=15) CD19-, CD20-, or BCMA-targeted CAR-T-cell therapy, as well as controls (n=8).

Individuals post-CAR-T-cell therapy were in remission.

We tested for antibodies to 4 vaccine strains at baseline and ≥1 time point after IIV using neutralization and hemagglutination inhibition assays.

An antibody response was defined as a ≥4-fold titer increase from baseline at the first post-vaccine time point.

Baseline A(H1N1) titers in the CAR-T cohorts were significantly lower compared to controls.

Antibody responses to ≥1 vaccine strain occurred in 2 (29%) individuals before CAR-T-cell therapy; one individual maintained a response for >3 months post-CAR-T-cell therapy.

Antibody responses to ≥1 vaccine strain occurred in 6 (40%) individuals vaccinated after CAR-T-cell therapy.

An additional 2 (29%) and 6 (40%) individuals had ≥2-fold increases (at any time) in the pre- and post-CAR-T cohorts, respectively.

There were no identified clinical or immunologic predictors of antibody responses.

Neither severe hypogammaglobulinemia nor B-cell aplasia precluded antibody responses.

These data support consideration for vaccination before and after CAR-T-cell therapy for influenza and other relevant pathogens such as SARS-CoV-2, irrespective of hypogammaglobulinemia or B-cell aplasia.

Larger studies are needed to determine correlates of vaccine immunogenicity and durability in CAR-T-cell therapy recipients.